Parker Institute for Cancer Immunotherapy
Search
Search Close

Early Career Researchers

Investing in Next Generation Talent

We have an ambitious mission. Not only do we invest in the talent of today, we train the cancer immunotherapy leaders of tomorrow. Our financial support, access to cutting-edge technology, impressive network of scientists, and resources empower the next generation of leaders. With PICI, these early career researchers can take bold questions and big ideas and turn them into research that has the potential to transform immunotherapy treatments.

Meet Our 2022 Awardees

39

NO. OF AWARDS SINCE 2016

$19 Million

TOTAL AMOUNT AWARDED

Related

Parker Scholars, Bridge Fellows and Senior Fellows

Since our inception, we’ve been planning for the future. And the brightest young investigators in cancer immunotherapy are the future. In 2016, we launched the Parker Scholars, Parker Bridge Fellows and Parker Senior Fellows to support the most ambitious early career researchers. Risk-taking is required. New thinking is mandatory. We challenge them to explore their boldest ideas to propel the field forward. We equip them with cutting-edge tools and technologies. We give them access to data from clinical trials and pre-published papers. We connect them with leading researchers and their peers in cancer immunotherapy. We do our part so they can focus on advancing their science. The end goal: a future where we don’t have to fear cancer.

  • Parker Scholars: Graduate students and researchers entering their first postdoctoral appointment who are focused on high-impact, high-risk projects.
  • Parker Bridge Fellows: Senior postdoctoral investigators transitioning to faculty positions who want to answer the most critical questions in cancer immunotherapy.
  • Parker Senior Fellows: Senior researchers who have recently completed their MD or PhD degree and are ready to establish independent programs in cancer immunotherapy.